Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study.
Journal: The Lancet. Haematology
Published: March 05, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.
Journal: Lancet (London, England)
Published: August 22, 2024
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 10, 2021
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 11, 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Journal: Leukemia
Published: February 27, 2019
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Journal: Clinical epigenetics
Published: March 22, 2016
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Journal: Nature medicine
Published: December 04, 2014
The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: August 01, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Journal: British journal of haematology
Published: June 10, 2014
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.
Journal: Haematologica
Published: April 22, 2014
Last Updated: 09/26/2026